Mankind Pharma Reports Strong Q1 FY27 Results with Consolidated Net Profit Rising 29% to ₹574.09 Crore

Mankind Pharma Limited has announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026 (Q1 FY27). The pharmaceutical major posted strong top-line and bottom-line growth on both standalone and consolidated levels, driven by robust operational performance across its business segments.

Consolidated Financial Highlights

On a consolidated basis, Mankind Pharma reported a 29.12% year-on-year increase in Net Profit After Tax (PAT), reaching ₹574.09 crore for Q1 FY27, compared to ₹444.62 crore in the corresponding period of the previous fiscal year (Q1 FY26). Profit attributable to equity holders of the parent stood at ₹568.06 crore, while non-controlling interests accounted for ₹6.03 crore.

Total consolidated income grew 11.65% year-on-year to ₹4,075.59 crore in Q1 FY27, up from ₹3,650.23 crore reported in Q1 FY26.

Revenue from Operations: Expanded 12.89% year-on-year to ₹4,030.59 crore, up from ₹3,570.35 crore in Q1 FY26.

Other Income: Stood at ₹45.00 crore, compared to ₹79.88 crore in Q1 FY26.

Profit Before Tax (PBT): Climbed 42.36% year-on-year to ₹769.45 crore, compared to ₹540.49 crore in Q1 FY26.

Total Expenses: Stood at ₹3,310.08 crore in Q1 FY27 against ₹3,112.91 crore in Q1 FY26. Employee benefits expense accounted for ₹913.50 crore, while raw material and component costs totaled ₹684.85 crore.

Total Comprehensive Income: Came in at ₹553.78 crore, compared to ₹443.86 crore in the year-ago period.

Standalone Performance Overview

On a standalone basis, Mankind Pharma delivered solid revenue expansion and profit growth:

Revenue from Operations: Grew 15.35% year-on-year to ₹2,964.05 crore in Q1 FY27 from ₹2,569.73 crore in Q1 FY26.

Total Income: Reached ₹2,998.01 crore compared to ₹2,634.94 crore in Q1 FY26.

Profit Before Tax (PBT): Advanced 52.48% year-on-year to ₹756.57 crore from ₹496.17 crore in Q1 FY26.

Net Profit After Tax (PAT): Increased by 34.49% year-on-year to ₹558.49 crore in Q1 FY27 compared to ₹415.27 crore in Q1 FY26.

Total Expenses: Stood at ₹2,241.44 crore for the quarter, compared to ₹2,138.77 crore in Q1 FY26.

Key Financial Ratios & Per Share Metrics

Per Share Information

Consolidated EPS: Basic Earnings Per Share (EPS) for Q1 FY27 increased to ₹13.76 per share (face value ₹1.00), compared to ₹10.62 in Q1 FY26. Diluted EPS stood at ₹13.74.

Standalone EPS: Basic EPS for Q1 FY27 rose to ₹13.53 per share against ₹10.06 in Q1 FY26, with diluted EPS at ₹13.51.

Paid-Up Capital: Paid-up equity share capital remained steady at ₹41.30 crore (face value ₹1.00 per share).

Standalone Key Ratios (SEBI Reg 52/54 Disclosures)

Debt Equity Ratio: Improved to 0.25x as of June 30, 2026, down from 0.48x as of June 30, 2025 (and 0.34x as of March 31, 2026).

Interest Service Coverage Ratio (ISCR): Strengthened substantially to 8.61x from 3.89x in Q1 FY26.

Operating Margin: Expanded to 31% for Q1 FY27 on a trailing twelve months (TTM) basis, compared to 27% in Q1 FY26.

Net Profit Margin: Stood at 19% (TTM basis) for Q1 FY27, up from 16% in Q1 FY26.

Net Worth: Reached ₹16,967.03 crore as of June 30, 2026, compared to ₹14,763.59 crore as of June 30, 2025.

Shares of Mankind Pharma Limited was last trading in BSE at Rs. 2576.95 as compared to the previous close of Rs. 2592.55. The total number of shares traded during the day was 53754 in over 3568 trades.

The stock hit an intraday high of Rs. 2605.00 and intraday low of 2561.10. The net turnover during the day was Rs. 139153768.00.

Source : Equity Bulls

Keywords

MankindPharma INE634S01028 Pharmaceuticals Q1FY27 Q1FY2027 ResultUpdate